Despite a haemophilia market bustling with rivals, Qfitlia’s broad label and favourable dosing regimen could give it an upper hand.

Dose and frequency should be adjusted based on antithrombin activity, using the Innovance Antithrombin companion diagnostic test. The Food and Drug Administration (FDA) has approved Qfitlia ...

Soleo Health has been named the exclusive in-network specialty pharmacy for Qfitlia (fitusiran) by Sanofi, the first ...

WASHINGTON, D.C. — The U.S. Food and Drug Administration (FDA) has announced the approval of Qfitlia (fitusiran), a treatment designed to prevent or reduce the frequency of bleeding episodes in ...

Qfitlia (fitusiran), the first antithrombin-lowering therapy in hemophilia, offers consistent protection with as few as six injections a year via a prefilled pen or vial and syringe Unique mechanism ...

Sold as Qfitlia, the drug works by lowering the amount of a protein called antithrombin (AT); this helps increase the amount of thrombin, an enzyme essential for blood clotting. Qfitlia contains ...

Sanofi's Qfitlia, approved a few days ago by the FDA, offers a competitive edge in the hemophilia market with fewer injections and broader applicability than rivals. Despite Qfitlia's promising ...

The U.S. Food and Drug Administration has approved Qfitlia (fitusiran) for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients 12 years of age ...